Logo

BMS’ Camzyos (mavacamten) Receives the US FDA’s Approval for the Treatment of Symptomatic New York Heart Association Class II-III Obstructive HCM

Share this
BMS’ Camzyos (mavacamten) Receives the US FDA’s Approval for the Treatment of Symptomatic New York Heart Association Class II-III Obstructive HCM

BMS’ Camzyos (mavacamten) Receives the US FDA’s Approval for the Treatment of Symptomatic New York Heart Association Class II-III Obstructive HCM

Shots:

  • The approval was based on the P-III (EXPLORER-HCM) trial to evaluate Camzyos vs PBO in a ratio (1:1) in 251 adult patients with NYHA class II-III obstructive HCM to improve functional capacity & symptoms
  • The results showed that 37% vs 17% of patients achieved the composite 1EPs @30wk., greater improvement across all 2EPs including mean change from baseline post-exercise LVOT peak gradient & pVO2, improvement of NYHA class ≥1 (65% vs 31%)
  • Mean change from baseline in KCCQ-23 † CSS, KCCQ-23 TSS & KCCQ-23 PL, mean resting LVEF was 74% at baseline in both groups, 6% vs 2% experienced reversible reductions in LVEF to <50%. The company offers multiple programs and resources along with patients support

Ref: Businesswire | Image: Bristol Myers Squibb

Click here to­ read the full press release 

Neha

Neha Madan is a content writer at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions